Clinical Trial Update: HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

View source ↗

Summary

A completed trial CHANCE2416 studied hepatic arterial infusion chemotherapy in combination with PD-1 inhibitors and lenvatinib for high tumor burden advanced he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• PD-1 inhibitors

Snippet

Sponsor: First Hospital of China Medical University | Conditions: HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy | Status: COMPLETED